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Objectives: Over the last decade, various groups have proposed prognostic scoring systems for
patients with colorectal liver metastasis (CLM) treated with hepatic resection. The aims of the current
study were to evaluate the differences between and clinical importance of these prognostic scoring
systems and to determine their clinical applicability.
Methods: Relevant articles were reviewed from the published literature using the MEDLINE database.
The search was performed using the keywords ‘colorectal cancer’, ‘metastases’, ‘liver resection’ and
‘hepatectomy’.
Results: Twelve prognostic scoring systems were identified from 1996 to 2009. Six of these originated
from European institutions, three from Asian and three from North American centres. The median study
sample was 288 patients (range 81–1568 patients) and median follow-up was 35 months (range 16–52
months). All studies were retrospective in nature and the numbers of groups proposed by the various
scoring systems ranged from three to six. All the studies used the Cox proportional hazard model for
multi-variable analysis.
Conclusions: There is no ‘ideal’ prognostic scoring system for the clinical management of patients with
CLM for hepatic resection. These prognostic scoring systems are clinically relevant with respect to
survival but have not been used for risk stratification in controversial areas such as the administration of
chemotherapy or surveillance programmes.
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Introduction
At present, hepatic resection has become the optimal and only
treatment modality associated with longterm survival in patients
with colorectal liver metastasis (CLM). Despite the variability in
the selection criteria of patients with CLM for hepatic resection,
5-year survival rates up to 58% have been reported,1–3 and a recent
meta-analysis reported 10-year survival at 17–33%.4 These results
have repeatedly supported the clinical ‘controversy’ that both
longterm disease-free (>5 years)3 periods and potential cure (>10
years)2 can be achieved in certain patient groups following hepatic
resection compared with the survival outcome of patients with
non-resectable disease.5–7
In 1986, Ekberg et al. concluded that resection for CLM was
indicated only in patients with less than four liver metastases
including bilobar disease, no evidence of extrahepatic disease
and in whom a resection margin 10 mm could be achieved.8
Better understanding of hepatic segmental anatomy, refined hae-
mostatic techniques,9,10 ‘down-sizing’ chemotherapy and portal
vein embolization11 have increased the numbers of patients
undergoing hepatic resection to include some patients previ-
ously considered to be non-resectable. The current guidelines
state that the aims of liver resection in patients with CLM are to
remove all macroscopic disease, to achieve clear resection
margins and to leave sufficient functioning liver. These criteria
apply to patients with solitary, multiple and bilobar disease as
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well as patients with extrahepatic disease that is confined
to the lungs, spleen or adrenal glands.12 Although some
authorities may consider radical surgery to
be cyto-reductive only, the combination of resection of all
macroscopic disease with chemotherapy may improve
survival.13 The use of chemotherapy in this setting complements
the effect of hepatic resection in removing all macroscopic
disease.
Furthermore, studies have reported up to 40% survival at 5
years following repeat hepatic resection for recurrence of CLM,
with acceptable morbidity and mortality rates.14–17 Recent data
have suggested that patients with lung metastases of colorectal
origin have a 5-year survival following thoracotomy similar to that
observed in patients following resection of CLM.18,19 These results
reflect the adoption of a more aggressive approach towards the
treatment of metastatic colorectal disease.
To address the controversial topic of patient selection, various
groups have proposed using prognostic scoring systems to
stratify patients into risk categories in order to identify the
optimal clinical management strategy for each patient. Prognos-
tic scoring systems are believed to be advantageous with respect
to high-quality analyses, reproducibility between institutions
and clinical applicability, as well as being subject to consistent
external validation. The aims of the present systematic review
of all studies of prognostic scoring systems were to evaluate
the differences between and relevance of these prognostic
scoring systems and to determine their respective clinical
applicability.
Materials and methods
An electronic search was performed of the MEDLINE database for
the period 1980 to the present using the MeSH headings: ‘colorec-
tal cancer’, ‘liver metastases’, ‘liver resection’ and ‘hepatectomy’.
The search was limited to English-language publications and
papers reporting studies using human subjects. All titles and
abstracts were reviewed and appropriate papers were further
assessed. The reference sections of all papers deemed appropriate
were further reviewed to identify papers that might have been
missed on the primary search criteria.
Studies were included if they described or formulated a prog-
nostic scoring system based on demographic, clinical and/or
pathological variables that influenced the survival outcome for
patients undergoing liver resection for CLM (Fig. 1). All series
fitting the search specifications independent of the size of the
study population were included. The minimal dataset necessary
for inclusion required: details of CLM patients treated with
hepatic resection; documentation of survival, and a description of
the prognostic scoring system(s). Papers that provided adequate
survival data and identified prognostic variables but did not
include a prognostic scoring system were excluded. Case reports,
editorials, abstracts and reviews were also excluded.
Potential relevant studies identified
and screened for retrieval n = 1391
Studies retrieved for more detailed
evaluation n = 266 
Studies reporting sufficient data to be
included in review n = 12 
Studies included in review n = 12
Studies excluded n = 1125 
Case reports n = 134
Duplicate series n = 9
Non-radical treatment of CLM n = 598
Review articles n = 167
Non-English n = 153
Non-human n = 64    
Studies excluded n = 254 
Case reports n = 13
Duplicate series n = 29
Non-radical treatment of CLM n = 58
Review articles n = 56
No prognostic scoring system n = 98
Studies withdrawn n = 0 
Figure 1 Diagram demonstrating the search strategy used to identify studies to be included in this review. CLM, colorectal liver metastasis
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Prognostic scoring systems
To date, numerous studies have correlated a number of demo-
graphic, clinical, operative and pathological factors with disease-
free and overall survival of patients treated with hepatic resection
for CLM using statistical analysis comprising univariable and
multi-variable analyses.20–23 In comparison, there have been
limited publications on prognostic scoring systems.24–35 Based on
the current search criteria, 12 prognostic scoring systems were
identified from 1996 to 2009 (Table 1). The majority of the pro-
posed scoring systems originated from European institutions (n =
6; UK = 3, France = 1, Italy = 1, Germany = 1), followed by Asian
(n = 3; Japan = 2, South Korea = 1) and North American (n = 3)
centres. The median study sample was 288 patients (range
81–1568 patients) and the median follow-up was 35 months
(range 16–52 months). All studies were retrospective in nature
and the numbers of groups proposed by the various scoring
systems ranged from three to six. All the studies used the Cox
proportional hazard model for multi-variable analysis.
Nordlinger and co-workers were the first group to propose a
prognostic scoring system.24 It was based on their analysis of 1568
patients drawn from 85 institutions over a study period of 22 years
(1968–1990). The median follow-up in this study was 19 months
(range 9–30 months) and the majority of liver resections were
performed after 1987 (n = 918). Multi-variable analysis revealed
seven independent prognostic factors that included: age 60
years; serosal invasion of primary tumour; lymph node-positive in
the primary tumour; liver metastasis presenting within 2 years of
the primary tumour; liver metastasis sized5 cm; more than four
liver metastases, and a resection margin 1 cm. Their prognostic
scoring system divided patients into three groups and showed
2-year survival rates that decreased from 79% in the low-risk
group to 43% in the high-risk group. In addition, Nordlinger
et al.24 performed a bootstrap analysis for internal validation of
their prognostic scoring system.
Fong’s clinical risk score from the Memorial Sloan-Kettering
Cancer Center, New York is arguably the most well-known prog-
nostic scoring system. Fong and colleagues25 included 1001
patients in their study (1985–1998), which involved a median
follow-up of 22 months (range 0–89 months). The study identi-
fied seven independent prognostic variables derived from their
multi-variable analysis: lymph node-positive in the primary
tumour; a disease-free interval from primary to liver metastasis
12 months; more than one hepatic tumour; largest hepatic
metastasis 5 cm, carcino-embryonic antigen (CEA) level
>200 ng/ml; the presence of extrahepatic disease, and an involved
resection margin. Of these, margin involvement and the presence
of extrahepatic disease were the most influential and the authors
suggested that these characteristics should be considered con-
traindications to liver resection. In formulating their preoperative
scoring system, Fong et al.25 excluded patients with tumour
involvement at the resection margin and extrahepatic disease.
Using the first five preoperative variables described above, Fong’s
clinical scoring system showed a declining 5-year disease-free sur-
vival in patients scoring 0 (60%) compared with patients scoring
5 (14%).
Using a dataset that included 305 patients with CLM recorded
over 15 years, Iwatsuki and co-workers suggested a graded scoring
system using six groups and included both disease-free and overall
survival in their analyses.26 The median follow-up was 32 months.
Multi-variable analysis indicated that margin involvement, extra-
hepatic disease including lymph node involvement, more than
three liver metastases, bilobar distribution and an interval of
30 months between colorectal and liver resection were indepen-
dent prognostic variables. When 62 (20%) patients with margin
involvement or extrahepatic disease including lymph node
involvement were excluded, re-analysis revealed that more than
two liver metastases, tumour size8 cm, bilobar distribution and
an interval between colorectal and liver resection of 30 months
were independent predictors of poorer disease-free survival.
These four variables were used in the scoring system. The authors
identified six groups in total: grade 1 patients showed no risk
factors; grade 2 patients had one risk factor; grade 3 patients had
two risk factors, and so forth. The last group (grade 6) consisted of
patients with either margin involvement or extrahepatic disease.
This group of patients had no 5-year survivors, whereas 48% of
grade 1 patients survived to 5 years.
Ueno et al. proposed a prognostic scoring system comprising
three stages (A–C) following analysis of 85 patients with CLM
over an 11-year study period.27 This study had a median follow-up
of 52 months (range 13–118 months) and 5-year disease-free and
overall survival rates of 21% and 28%, respectively. Multi-variable
analysis identified marked tumour budding and lymph node posi-
tivity of the primary tumour, liver metastasis at <1 year after
primary resection and three or more liver metastases as indepen-
dent predictors of poorer overall survival. Tumour budding was
defined as micro-tubular cancer nests or microscopic clusters of
undifferentiated cancer cells. Hence, the scores were calculated as
follows: stage A (none or either liver metastasis at <1 year or three
or more liver metastases); stage B (primary tumour aggressiveness
or both liver metastasis at <1 year and three or more liver
metastases), and stage C (all three risk factors). There were no
5-year survivors among patients (n = 9) in stage C. In addition,
rates of disease recurrence within 6 months were reported at 7%,
30% and 44%, in stages A, B and C, respectively.
Lise and colleagues published their scoring system in 2001
based on a survey of patients conducted over 20 years (1977–
1997).28 The median follow-up was 52 months. The endpoint of
this study was the identification of variables influencing disease-
free survival, diffuse recurrence within 6 months and recurrences
suitable for surgery. Multi-variable analysis of 20 variables iden-
tified five adverse prognostic variables: >30% liver invasion;
lymph node-positive primary tumour; more than one liver
metastasis; serum glutamic pyruvic transaminase (GPT) levels
55 U/l, and non-anatomical hepatic resection. Of note, this
study did not include pathological data with respect to resection
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margin because histological samples were available for only 31%
(n = 42) of cases. The scoring system devised by Lise et al.28
resulted in three groups, of which group A included patients with
the best prognosis (80%), in whom the authors observed a declin-
ing 3-year disease-free survival, and group C included patients
with the worst prognosis (10%).
Nagashima et al. developed a formula for a prognostic scoring
system in 2004 and divided patients into three grades (A–C), with
grade C having the worst prognosis.29 The median follow-up of 81
patients undergoing hepatectomy from 1981 to 1997 was 36
months (range 4–156 months). Cox regression analysis indicated
that serosal invasion of the primary tumour, lymph node-positive
primary disease, non-resectable extrahepatic disease, more than
one liver metastasis and tumour size 5 cm were independent
prognostic variables. Grade A patients had a 5-year overall sur-
vival of 85%, by contrast with grade C patients, none of whom
survived to 5 years. In addition, the study by Nagashima et al.29
was the first to undergo external validation of its prognostic
scoring system, using 70 patients undergoing hepatectomy in
another Tokyo centre, which concluded similar findings.
Schindl et al. published a suggested prognostic scoring system
in 2005 following retrospective analysis of 270 patients referred
to their institution in Edinburgh, UK over a 14-year period.30
Schindl et al. included non-resectable cases in their scoring system
and 150 (56%) of their patients were treated with hepatic resec-
tion.30 This study had a median follow-up of 16 months and
reported overall 5-year survival rates for the original cohort and
for patients who underwent hepatic resection of 15% and 36%,
respectively. The independent prognostic variables identified
included Duke’s stage of primary tumour, serum CEA, alkaline
phosphatase and albumin levels and number of liver metastases.
Patients were divided into three groups based on their calculated
score, namely, the good, moderate and poor prognosis groups.
Irrespective of their groups, patients who underwent hepatic
resection had significantly better outcomes compared with
patients treated palliatively. Nevertheless, the poor prognosis
group (n = 12) did not have any 5-year survivors following hepa-
tectomy, and the good and moderate prognosis groups demon-
strated 5-year survival rates of 63% and 20%, respectively. This
prognostic scoring system was externally validated in 193 patients
referred to another institution (in Vienna, Austria) and similar
findings were reported.
Malik and co-workers developed a preoperative scoring system
following analysis of 687 patients who underwent hepatectomy
over a period of 13 years.31 The endpoint of this study was the
identification of variables influencing both disease-free and
overall survival. The median follow-up was 34 months (range
12–168 months) and overall 5-year survival was 45%. Multi-
variable analysis revealed the presence of eight or more liver
metastases and an inflammatory response to tumour (IRT) to be
independent predictors of poorer disease-free and overall sur-
vival. Inflammatory response to tumour was defined by an
elevated C-reactive protein (C-RP) level (>10 mg/l) or raised neu-
trophils : lymphocyte ratio (5). Based on these results, a preop-
erative prognostic score was developed, on which 0 = no risk
factors, 1 = either IRT or eight or more liver metastases, and 2 =
both IRT and eight or more liver metastases. Patients who scored
0 and 1 had 5-year overall survival rates of 49% and 34%, respec-
tively. By contrast, there were no 5-year survivors among patients
who had both prognostic factors (n = 23, median survival = 21
months).
Zakaria and co-authors proposed their ‘Mayo scoring system’
following retrospective analysis of 662 consecutive patients who
underwent hepatectomy over 35 years.32 The endpoint of this
study was to determine prognostic variables that influenced both
disease-free survival and recurrences. The median follow-up was 3
years (range 5 days–37 years) and overall 5-year survival was 37%.
This study also reported a 65% probability of recurrences at any
site at 5 years. Multi-variable analysis showed that a poorer
disease-free survival was significantly associated with liver
metastasis within 30 months of primary colorectal tumour diag-
nosis, hepatic metastases sized8 cm, perioperative blood trans-
fusion and positive hepatoduodenal lymph nodes. Zakaria et al.32
divided patients into three groups: group 1 (patients with any risk
factor except blood transfusion and positive hepatoduodenal
lymph nodes); group 2 (patients with any risk factor except posi-
tive hepatoduodenal lymph nodes), and group 3 (patients with
positive hepatoduodenal lymph nodes with or without other risk
factors). Five-year disease-free survival was 55% in group 1, 39%
in group 2 and 20% in group 3. Zakaria et al.32 further analysed
the applicability of three other scoring systems (by Nordlinger
et al.,24 Fong et al.25 and Iwatsuki et al.26) using their patient popu-
lation and observed that neither survival nor recurrence among
their population sample was stratified discretely by any of these
three scoring systems.
Lee and colleagues devised a prognostic scoring system for
patients undergoing simultaneous resection of the colorectal
primary and synchronous liver metastases based on their 11-year
experience.33 All 135 patients included in their survival analysis
had a clear liver resection margin. The median follow-up was 47
months (range 12–134 months). Multi-variable analysis showed a
resection margin 5 mm, CEA levels >5 ng/ml, four or more
node-positive primaries and more than one liver metastasis to be
independent adverse prognostic variables. Lee et al.’s33 prognostic
scoring system comprised low (0–1), intermediate (2) and high
(3–4) risk groups depending on the number of prognostic vari-
ables. Declining 5-year overall survival rates of 46%, 41% and
11% were observed in the low-, intermediate- and high-risk
groups, respectively.
Rees et al. formulated a prognostic scoring system incorporat-
ing both pre- and postoperative variables based on a series of 929
patients who underwent hepatic resection for CLM over 18
years.34 In this series, median survival was 42 months and 5- and
10-year cancer-specific survival rates were 36% and 23%, respec-
tively. Statistical analysis included 80 patients who underwent
re-resection. The multi-variable analysis included prognostic vari-
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ables with a P-value <0.25 on univariate analysis. Prognostic
factors found to be significant on multi-variable analysis were
more than one liver metastasis, a lymph node-positive primary, a
poorly differentiated primary, extrahepatic disease, tumour size
5 cm, CEA >60 ng/ml and an involved resection margin. The
first six variables were used in the preoperative score and the last
six in the postoperative score. Patients were divided into five
groups according to their scores. Patients showed similar 5-year
overall survival rates for pre- and postoperative scores in all five
groups. For example, patients with the lowest scores (0) had a pre-
and postoperative 5-year survival of 64%, whereas patients with
the highest scores (>15) had a pre- and postoperative 5-year sur-
vival of 2%. Similarly to Nordlinger et al.,24 Rees and co-workers34
also performed internal validation of their scoring system using
bootstrap analysis with 50% of their study sample.
The most recent prognostic scoring system was devised by
Konopke and co-authors based on their analysis of 201 patients
over 13 years.35 The median follow-up was 31 months (range
6–143 months) and the authors included both disease-free and
overall survival in their analyses. The disease-free and overall
5-year survival rates were 28% and 43%, respectively. Only
patients with a clear resection margin were included in the analy-
sis. Multi-variable analysis identified synchronous colorectal
primary and liver metastases, the presence of four or more liver
metastases and CEA >200 ng/ml as adverse prognostic factors.
Patients were divided into three groups, of which the high-risk
group (patients with two or more of these variables) had a median
survival of 38 months, whereas the low-risk group (patients who
did not exhibit any of these variables) had a median survival of 67
months. Internal validation of this scoring system was performed
using bootstrap analysis.
Discussion
The ‘ideal’ scoring system
None of the studies based on the current available prognostic
scoring systems were without limitations; hence the ‘ideal’ scoring
system has not yet been established. All these studies were based
on retrospective data and many series included patients operated
on during the 1970s and 1980s. Selection of patients for hepatic
resection was previously stringent because the risk for postopera-
tive morbidity and mortality was significant, the accuracy of
radiological imaging for preoperative staging for metastatic
disease was limited and the survival outcome following surgery
was undetermined. During this time period there were many
major developments in hepatic resectional surgery, not only in
terms of surgical technique, but also, importantly, in relation to
anaesthesia and perioperative care, and thus the overall results
may underestimate true outcomes following resection in CLM.
This has cemented hepatic resection as the treatment of choice for
CLM, including staged hepatic resection following neoadjuvant
chemotherapy36 and portal vein embolization.11
A number of risk factors have been consistently reported as
important in predicting a poorer outcome following resection for
CLM, including: number and size of hepatic metastases; presence
of extrahepatic disease; high serum CEA levels; synchronous
primary colorectal carcinoma and hepatic metastases; lymph
node-positive primary tumour; presence of IRT, and involved
resection margin. Nevertheless, the published studies have been
inconsistent in identifying these variables as independent predic-
tors of survival on multi-variable analyses in different datasets,
which suggests that certain prognostic variables may be more
significant in certain patient groups. One possible explanation for
this observation may involve the sample size of these studies. All
the published studies were retrospective and therefore none
included a power calculation. Although some studies did include
substantial numbers of patients, many of them were left with very
small sample sizes when the patients were divided into subgroups
according to the proposed scoring systems, especially those with
more than three risk groups. Length of follow-up may be another
factor contributing to this inconsistency in identifying significant
prognostic variables. The median follow-up for the 12 studies
reviewed here was 35 months. Certain prognostic factors that are
significant in studies with shorter follow-up periods tend to be less
accurate in predicting overall survival and recurrences in studies
with longer follow-up data. Hence, prognostic models that are
based on shorter durations of follow-up may not be accurate or
representative in predicting survival and recurrences. Another
reason for this discrepancy between institutions in identifying
significant prognostic factors may involve limitations of the data
available for analysis. Certain studies, such as that by Lee et al.,
included multiple variables for survival analysis, among which
were various factors related mainly to the primary tumour.33
Certain ‘unique’ prognostic factors were analysed only by certain
authors, such as tumour budding, analysed by Ueno et al.,27 and
IRT, analysed by Malik et al.,31 whereas some important prognos-
tic markers were omitted from statistical analysis by other authors,
such as resection margin, which was omitted by Lise et al.28 In
addition, well-recognized prognostic factors, such as number of
liver metastases, were grouped differently by the various studies.
Nordlinger et al.24 observed that more than four liver metastases
was a significant prognostic factor, whereas Lise et al.28 and
Nagashima et al.29 reported the presence of more than one liver
metastasis as an adverse prognostic variable. It should also be
noted that not all studies had the same endpoint when analysing
these prognostic variables. The majority of authors analysed vari-
ables with overall patient survival as their endpoint, with the
exception of Fong et al.,25 Lise et al.28 and Zakaria et al.,32 who
focused on disease-free survival only. Three groups (Iwatsuki
et al.,26 Malik et al.31 and Konopke et al.35) addressed a combina-
tion of both disease-free and overall survival in their analyses.
These scoring systems also differed with respect to their inclu-
sion and exclusion criteria. Fong et al.25 excluded patients with a
positive resection margin and extrahepatic disease from their pre-
operative scoring system. Similarly, Iwatsuki and co-workers26
excluded patients with a positive resection margin and/or extra-
hepatic disease, including lymph nodes, as these patients had the
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worst survival outcome. Lee et al.33 and Konopke et al.35 included
only patients with a clear resection margin. Schindl and col-
leagues30 described the only series to include both surgically
managed and non-resectable cases in their scoring system. Only
the studies by Fong et al.25 and Rees et al.34 included patients who
underwent re-resection. The exclusion of patients with a positive
resection margin following resection for CLM is controversial.
Recently, Bodingbauer et al. observed that resection margin and
size of margin width did not correlate significantly with survival
following resection for CLM.37 In a series of 1019 patients, Are and
co-investigators demonstrated that a resection margin >1 cm was
an independent predictor of survival following resection for
CLM.21 However, Figueras et al. showed that a margin width
<1 cm in patients who underwent resection for CLM did not
significantly influence recurrence of disease in a cohort of 609
patients.38 Other authors have reported similar findings.39 In cases
with multiple and/or large hepatic metastases, it may be difficult
to obtain a clear resection margin of 1 cm even with procedures
such as hemi-hepatectomy or tri-sectionectomy. In addition, the
role of adjuvant chemotherapy in cases with microscopic tumour
involvement at the resection margin is still unknown. The inclu-
sion of re-resection patients in the same analysis as patients
undergoing primary hepatic resection may skew statistical analy-
sis, as these patients are likely to have a better survival as a result of
treatable recurrences.
Like the advances in diagnostic, anaesthetic and surgical tech-
niques over the last three decades, the use of chemotherapy in a
neoadjuvant or adjuvant setting has contributed to the improved
survival outcome for patients with CLM.40 Some authorities have
suggested that preoperative chemotherapy can potentially
improve survival, especially in cases of initially inoperable
metastases, principally confined to the liver, which are converted
into operable disease. However, there is concern that patients
treated with neoadjuvant chemotherapy have increased morbidity
and mortality following hepatic resection.41,42 Nevertheless, neo-
adjuvant chemotherapy has contributed to the increase in indica-
tions for resection in CLM. Five prognostic scoring systems did
not include chemotherapy as part of their statistical analyses.
Nordlinger et al. showed patients (35%) who received adjuvant
chemotherapy did not have a significantly different overall sur-
vival compared with patients who did not have chemotherapy.24
However, the study did not provide details of its chemotherapy
protocol and, given that 85 centres contributed towards this series,
it is likely that there were no standard protocols for the whole
population sampled. The time period of this study would also
suggest that chemotherapy agents such as oxaliplatin were not
used. Iwatsuki et al.26 and Zakaria et al.32 reported no significant
influence of adjuvant chemotherapy with respect to survival.
However, these two groups reported on long study periods and
thus included patients treated in the 1970s and 1980s. Malik and
co-investigators observed that neoadjuvant chemotherapy did not
significantly alter the survival outcome of patients with CLM
following hepatectomy.31 Nevertheless, patients who received
oxaliplatin-based neoadjuvant chemotherapy represented only
10% (n = 71) of their series. Following simultaneous resection of
synchronous colorectal carcinoma and hepatic metastases, Lee
et al. did not show an improved overall survival in patients treated
with adjuvant chemotherapy (n = 112, 81%) compared with
patients who did not have chemotherapy.33 Rees et al.34 and
Konopke et al.35 documented no significant survival differences
with the use of adjuvant chemotherapy following resection of the
primary colorectal tumour.34 Rees and co-workers34 did not
perform a subgroup analysis of CLM patients who underwent
down-sizing chemotherapy (n = 105, 21%) with respect to sur-
vival. Further subgroup analysis of patients who underwent neo-
adjuvant 5-fluorouracil-based chemotherapy (n = 43, 21%) by
Konopke et al.35 revealed a significant survival difference in
patients in the ‘high-risk’ group, who were given preoperative
chemotherapy and hepatic resection, compared with patients
treated with resection only. Based on these results, chemotherapy,
irrespective of whether it is delivered pre- or postoperatively, does
not appear to influence the longterm outcome of patients with
CLM treated with hepatic resection and hence its inclusion as a
variable within the prognostic scoring system does not seem jus-
tified. However, these studies involved long study periods, differ-
ent chemotherapy regimens and non-standard protocols, which
may have contributed to the non-significance of chemotherapy on
statistical analysis. Certainly, more studies are required to confirm
this and hence the role of chemotherapy in a prognostic scoring
system should not be discounted.
Prognostic scoring models for patients with CLM require inter-
nal and external validation before they can be widely imple-
mented. With respect to data validation, only Nordlinger et al.,24
Rees et al.34 and Konopke et al.35 performed internal validation of
their scoring systems based on a data re-sampling technique with
bootstrap analysis. Bootstrapping is a widely accepted method
for internal validation, but is known to be labour-intensive.
Nagashima et al.29 and Schindl et al.30 performed external but not
internal validation of their results. External validity of a prognos-
tic scoring system can be analysed by a variety of methods, includ-
ing prospective, independent, multi-institutional and multiple
validation with different follow-up periods.43 The remaining
studies reported no data validation. All but one study suggesting a
prognostic scoring system was based on a single-centre experi-
ence. Nordlinger et al.24 was the only study to propose a scoring
system based on analysis of a multi-institution dataset. Since these
scoring systems were proposed, various authors have attempted to
address their usefulness in clinical practice. Mann et al.44 observed
that their study population validated the clinical risk score devised
by Fong et al.25 and found it to be highly predictive of patient
survival. Other authors have documented similar results.45,46
However, there have also been conflicting results with regard to
the usefulness of these scoring systems. Zakaria et al.32 failed to
confirm predictive stratification of their patients with CLM
undergoing hepatic resection using the prognostic scoring systems
proposed by Nordlinger et al.,24 Fong et al.25 and Iwatsuki et al.26
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Although robust statistical analysis may ensure prognostic scoring
system reliability, this does not guarantee the applicability of pre-
dictive stratification of patients with the same disease between
different institutions.
Clinical application
In terms of clinical application, the principal issues concern the
accuracy of the scoring systems proposed by the various groups in
the clinical management of patients with CLM. These prognostic
scoring systems were designed to refine patient selection for resec-
tion of CLM and to facilitate patient stratification into risk or
prognostic groups for clinical management. All the prognostic
scoring systems proposed are based on a solid foundation of sta-
tistical analyses of their respective datasets. Nevertheless, this does
not guarantee ‘generalizability’. The clinical usefulness of a prog-
nostic system is established by its being tested and found accurate
across increasingly diverse settings. Furthermore, however accu-
rate statistical analysis may be, it does not mean that data or a
prognostic model from one institution will fit into another insti-
tution’s dataset addressing the same disease. Invariably, selection
biases, population differences, differences in groups of variables,
differences in length of follow-up, changes in radiological imaging
and improvements in surgical techniques will come into play. In
studies that analyse disease-free survival and recurrences, this can
vary considerably between institutions according to the different
surveillance protocols implemented. The time-point at which
recurrences are detected will invariably depend on the frequency
of surveillance following resection in patients with CLM.
In accordance with current guidelines, patients with CLM suit-
able for surgery would be offered surgery with the aim of resecting
all macroscopic disease with a clear margin and leaving sufficient
liver remnant. Hence, prognostic scoring systems to select patients
for resection would be considered obsolete. All patients with
resectable disease, irrespective of the number and size of hepatic
metastases, should be treated with hepatic resection, and a sub-
group of patients who may be suitable for further pre-surgical
treatment, such as down-sizing chemotherapy or portal vein
embolization, should be treated accordingly prior to reassessment
for surgery. Prognostic scoring systems allow the identification of
patient groups at higher risk of recurrence and poorer survival,
and their main role in clinical management may be to identify
patients who would benefit from further intensive postoperative
radiological surveillance.
Chemotherapy
The exact timing and role of chemotherapy in patients with resec-
table metachronous liver metastases represent an area of intense
debate. With respect to synchronous liver metastasis, the optimal
timing of and indication for surgical resection are even less
defined, especially with regard to the unclear boundary between
simultaneous resection followed by adjuvant chemotherapy vs.
neoadjuvant chemotherapy followed by liver resection. Although
most authorities would agree that patients with CLM would
benefit from chemotherapy, there is controversy as to preferences
for preoperative vs. postoperative chemotherapy.47 This is partly in
response to studies that have reported a significant association
between the administration of neoadjuvant chemotherapy and
increased morbidity and mortality following hepatectomy for
CLM.41 Oxaliplatin-based regimes are known to cause sinusoidal
obstruction syndrome, which leads to impaired regeneration and
increases the risk for liver failure after major liver resections.48
Vauthey et al. observed that administration of irinotecan caused
chemotherapy-associated steatohepatitis (CASH) that was associ-
ated with increased postoperative mortality, specifically deaths
from postoperative liver failure.41 Nevertheless, a recent random-
ized trial by Nordlinger and co-authors observed that patients
who received chemotherapy (FOLFOX4: oxaliplatin, leucovorin
and fluorouracil regimen), either prior to or following hepatic
resection for CLM, had a significant reduction in the risk for
progression compared with patients who had surgery only.40 In
the subgroup of patients with initially non-resectable disease, the
use of neoadjuvant chemotherapy can be used as a down-sizing
technique to enable resection.13
The management of patients with potentially curative CLM
requires a multidisciplinary approach. A sub-set of patients would
benefit from enrolment into multimodal treatment procedures
with chemotherapy and resection. However, it is unclear whether
to prefer simultaneous resection followed by adjuvant chemo-
therapy or neoadjuvant chemotherapy followed by liver resection.
Ultimately, the decision about which therapeutic procedure to
follow in synchronous CLM remains subjective and depends on
the expertise and aggressiveness of the surgeon. None of the
current prognostic scoring systems included chemotherapy as a
prognostic factor because of its failure to achieve statistical sig-
nificance. However, Konopke et al.35 did report that neoadjuvant
chemotherapy improved the survival of high-risk patients who
underwent both chemotherapy and resection compared with
those who underwent resection only. This is an important area in
which a preoperative prognostic scoring system would be clini-
cally useful in stratifying patients who would benefit from either
neoadjuvant or adjuvant chemotherapy. More studies are needed
to determine the suitability of chemotherapy in an adjuvant or
neoadjuvant setting.
Surveillance
Historically, patients with disease recurrence following resection
for CLM were considered to have a poor prognosis, few patients
were offered repeat liver resections49,50 and, hence, intensive sur-
veillance follow-up could not be justified. However, as more
hepatobiliary units are adopting an aggressive surgical approach
towards hepatic and/or extrahepatic recurrences following cura-
tive resection for CLM, an intensive surveillance programme
designed to detect recurrences where surgical intervention can
alter survival outcome is crucial. Prognostic scoring systems
could play a role in determining the frequency of radiological
imaging required by patients with CLM following hepatectomy.
HPB 235
HPB 2010, 12, 227–238 © 2010 International Hepato-Pancreato-Biliary Association
Not all patients would require the same intensive follow-up pro-
tocol. Beard et al.51 and Gazelle et al.52 have suggested a selective
approach in surveillance based on cost : benefit ratio analysis.
Bhattacharjya et al. recently evaluated a prospective intensive
follow-up programme using serial tumour marker estimations
and contrast-enhanced computed tomography (CT) of the chest
and abdomen in patients undergoing potentially curative resec-
tion of colorectal liver metastases.53 This series showed that none
of their eight patients with recurrent liver metastases within 6
months of hepatic surgery had resectable disease.53 Similarly,
Metcalfe et al. identified only one of 22 potentially curable recur-
rences within 12 months of liver resection using a 6-monthly CT
surveillance protocol.54 However, both these studies were limited
by small sample sizes. Although the first 2 years of follow-up after
resection for CLM have been recognized as representing the
period when disease is most likely to recur,55 the frequency of
radiological imaging during this period is controversial. The
majority of hepatobiliary units offer either 3- or 6-monthly sur-
veillance follow-up during this period.14,25,37,38,53 Nevertheless,
cost : benefit analysis must be considered carefully when design-
ing surveillance protocols. The timing and pattern of disease
recurrence, its implication for surgical and/or medical interven-
tion and its subsequent effect on patient outcomes are crucial to
the design of surveillance protocols. Positron emission tomogra-
phy (PET) may be an imaging modality of choice in future pro-
tocols for surveillance after surgery for CLM. A recent study by
Fernandez and co-workers reported that patients staged preop-
eratively with PET had a 5-year overall survival of 58% following
hepatic resection.1 In addition, other authors have found that
PET frequently detects recurrent and metastatic colorectal cancer
in patients with normal CT scans, but rising CEA levels.56,57 There
are few considerations with regard to the cost and availability of
PET to be taken into account prior to its widespread use. To date,
no published studies have assessed the intervals and duration of
surveillance with respect to prognostic variables following
hepatic resection for CLM.
Conclusions
Currently, there is no ideal prognostic scoring system for the clini-
cal management of patients with CLM for hepatic resection.
Because of its potential for cure and longterm disease-free sur-
vival, hepatic resection should be offered to all patients with CLM
in whom macroscopic disease can be addressed. Although these
prognostic scoring systems are clinically relevant with respect to
survival, their broad application currently has limited value with
respect to patient stratification for clinical management. Any
future prognostic scoring system should address patient selection
for neoadjuvant or adjuvant chemotherapy and determine the
surveillance protocol required by patients following hepatic resec-
tion for CLM. Designing the ‘ideal’ prognostic scoring system is
clearly the next step.
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